Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 39INDUSTRY 38NIH 19NETWORK 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 13Neoplasms 11Breast Neoplasms 11Carcinoma, Hepatocellular 10Prostatic Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Rectal Neoplasms 5Anastomotic Leak 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Lymphoma, Follicular 4Stomatitis 3Pancreatic Neoplasms 3Multiple Myeloma 3HIV Infections 3Disease 3Depression 3Vulvar Neoplasms 2Surgical Wound Infection 2Sleep Initiation and Maintenance Disorders 2Skin Neoplasms 2Sarcoma 2Postoperative Complications 2Peritoneal Neoplasms 2Neuroendocrine Tumors 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Motor Activity 2

Interventions

Poly(ADP-ribose) Polymerase Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Fallopian Tube Neoplasms × 90 days × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡